Health Canada Products Safety Reviews
March 17, 2021
Correspondence from the Marketed Health Products Directorate regarding the summary safety review for Diuretics, Including Acetazolamide – Assessing the Potential Risk of Certain Eye Disorders is available here.
Correspondence from the Marketed Health Products Directorate regarding the summary safety review for Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept) and Erelzi (biosimilar etanercept) – Assessing the Potential Risk of Mycosis Fungoides is available here.
February 02, 2021
Correspondence from the Marketed Health Products Directorate regarding the summary safety review for Ceftriaxone-containing products – Assessing the Potential Risk of Encephalopathy is available here.
January 26, 2021
Correspondence from the Marketed Health Products Directorate regarding the summary safety review for Sofosbuvir-containing products – Assessing the Potential Risk of Severe Cutaneous Adverse Reactions (SCAR) is available here.
January 07, 2021
Correspondence from the Marketed Health Products Directorate regarding the summary safety review for Tamiflu (oseltamivir) and generics – Assessing the Potential Risk of Haemorrhages is available here.
January 05, 2021
Correspondence from the Marketed Health Products Directorate regarding the summary safety review for Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) and the Potential Risk of Sexual Dysfunction despite Treatment Discontinuation is available here.
December 24, 2020
Correspondence from the Marketed Health Products Directorate regarding the summary safety review for Tramadol-containing products – Assessing the Potential Risk of Hallucinations is available here.
December 07, 2020
Correspondence from the Marketed Health Products Directorate regarding the summary safety review for Clobazam-containing products – Assessing the Potential Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is available here.
December 01, 2020
The Marketed Health Products Directorate regarding the summary safety review for Bacitracin for Injection Products and the potential risks of Nephrotoxicity and Anaphylactic Reactions is available here. The summary safety review is available here.
For the Marketed Health Products Directorate regarding the summary safety review for Direct-acting antiviral products containing a Protease Inhibitor and the Potential Risks of Hepatic Decompensation and Hepatic Failure click here. For the summary safety review, click here.
October 29, 2020
Re: Health Canada has published a summary safety review regarding Brilinta (ticagrelor).
The Summary Safety Review is available here